Patrick Neven

38.6k total citations · 7 hit papers
493 papers, 15.7k citations indexed

About

Patrick Neven is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Patrick Neven has authored 493 papers receiving a total of 15.7k indexed citations (citations by other indexed papers that have themselves been cited), including 272 papers in Oncology, 173 papers in Pulmonary and Respiratory Medicine and 146 papers in Cancer Research. Recurrent topics in Patrick Neven's work include Advanced Breast Cancer Therapies (144 papers), Estrogen and related hormone effects (121 papers) and Breast Cancer Treatment Studies (121 papers). Patrick Neven is often cited by papers focused on Advanced Breast Cancer Therapies (144 papers), Estrogen and related hormone effects (121 papers) and Breast Cancer Treatment Studies (121 papers). Patrick Neven collaborates with scholars based in Belgium, United States and France. Patrick Neven's co-authors include Ignace Vergote, Frédéric Amant, Philippe Moerman, Erik Van Limbergen, D. Timmerman, Hans Wildiers, Robert Paridaens, Marie-Rose Christiaens, Ann Smeets and Karin Leunen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Patrick Neven

468 papers receiving 15.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Endometrial cancer

2005 1.2k citations Frédéric Amant, Philippe Moerman et al. profile →
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

2017 1.1k citations George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology profile →
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

2019 590 citations George W. Sledge, Masakazu Toi et al. profile →
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer

2021 442 citations Giuseppe Floris, Christine Desmedt et al. profile →
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

2014 407 citations Martine Piccart, Gabriel N. Hortobágyi et al. Annals of Oncology profile →
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

2021 223 citations Hope S. Rugo, Patrick Neven et al. profile →
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

2021 161 citations Patrick Neven, Stephen Chia et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Neven Belgium	57	8.6k	5.0k	4.5k	3.1k	2.8k	493	15.7k
Gini F. Fleming United States	60	8.2k 0.9×	2.7k 0.5×	3.7k 0.8×	1.7k 0.6×	4.1k 1.5×	334	16.6k
Leslie G. Ford United States	32	4.3k 0.5×	3.7k 0.7×	3.5k 0.8×	4.8k 1.6×	2.6k 0.9×	74	13.2k
James N. Atkins United States	47	8.3k 1.0×	3.8k 0.8×	4.4k 1.0×	3.9k 1.2×	2.6k 0.9×	107	14.4k
Andrew G. Renehan United Kingdom	55	8.1k 0.9×	2.0k 0.4×	2.7k 0.6×	911 0.3×	4.2k 1.5×	181	16.1k
Eitan Amir Canada	57	8.8k 1.0×	3.9k 0.8×	3.6k 0.8×	1.3k 0.4×	2.6k 0.9×	416	15.4k
Victor G. Vogel United States	49	8.0k 0.9×	1.9k 0.4×	5.5k 1.2×	6.7k 2.2×	2.4k 0.8×	173	16.1k
Ping Sun Canada	47	4.9k 0.6×	1.2k 0.2×	4.4k 1.0×	4.2k 1.4×	2.8k 1.0×	128	10.9k
Andreas du Bois Germany	61	6.4k 0.7×	2.0k 0.4×	2.7k 0.6×	897 0.3×	1.8k 0.7×	445	15.8k
John Forbes United Kingdom	59	8.2k 0.9×	3.2k 0.6×	6.7k 1.5×	5.9k 1.9×	2.1k 0.8×	202	16.5k
André Robidoux Canada	36	7.7k 0.9×	1.5k 0.3×	8.0k 1.8×	4.4k 1.4×	2.2k 0.8×	89	14.7k

Countries citing papers authored by Patrick Neven

Since Specialization

Citations

This map shows the geographic impact of Patrick Neven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Neven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Neven more than expected).

Fields of papers citing papers by Patrick Neven

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Neven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Neven. The network helps show where Patrick Neven may publish in the future.

Co-authorship network of co-authors of Patrick Neven

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Neven. A scholar is included among the top collaborators of Patrick Neven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Neven. Patrick Neven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baelen, Karen Van, François Richard, Maria Margarete Karsten, et al.. (2025). Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study. Breast Cancer Research. 27(1). 106–106. 1 indexed citations

O’Shaughnessy, Joyce, Stephen Chia, Claudine Isaacs, et al.. (2023). 196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2. ESMO Open. 8(1). 101385–101385.

Campone, Mario, François‐Clément Bidard, Patrick Neven, et al.. (2023). AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer. Breast Cancer Research. 25(1). 141–141. 3 indexed citations

André, Fabrice, Faye Su, Nadia Solovieff, et al.. (2023). Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Annals of Oncology. 34(11). 1003–1014. 43 indexed citations

Neven, Patrick, Stephen Johnston, Masakazu Toi, et al.. (2021). MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer. Clinical Cancer Research. 27(21). 5801–5809. 7 indexed citations

Burris, Howard A., Arlene Chan, Aditya Bardia, et al.. (2021). Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. British Journal of Cancer. 125(5). 679–686. 52 indexed citations

Tambuyzer, Tim, Krizia Tuand, Victoria Depoorter, et al.. (2020). A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data. JNCI Journal of the National Cancer Institute. 112(10). 979–988. 24 indexed citations

Dezentjé, Vincent O., Jesse J. Swen, Dirk Jan A. R. Moes, et al.. (2019). Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. Journal of Clinical Oncology. 37(8). 636–646. 64 indexed citations

Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology. 35(25). 2875–2884. 1103 indexed citations breakdown →

10.

Groef, An De, Marijke Van Kampen, Marie-Rose Christiaens, et al.. (2015). Effectiveness of Postoperative Physical Therapy for Upper-Limb Impairments After Breast Cancer Treatment: A Systematic Review. Archives of Physical Medicine and Rehabilitation. 96(6). 1140–1153. 167 indexed citations

11.

Sonnenblick, Amir, Sylvain Brohée, Debora Fumagalli, et al.. (2015). Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. Oncotarget. 6(30). 30306–30316. 14 indexed citations

12.

Loibl, Sibylle, et al.. (2014). Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy - Reply. Journal of Clinical Oncology. 32(3). 255–256. 1 indexed citations

13.

Frederix, G. W. J., Johan L. Severens, Anke M. Hövels, et al.. (2014). Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium. European Journal of Cancer Care. 24(3). 340–354. 4 indexed citations

14.

Hatse, Sigrid, Diether Lambrechts, Annemieke Verstuyf, et al.. (2011). Low 25-hydroxyvitamin d3 serum levels are associated with larger breast tumor size. Annals of Oncology. 22. 60–60. 2 indexed citations

15.

Vandorpe, T., Hans Wildiers, Anne-Sophie Dieudonné, et al.. (2010). THE POSITIVE ASSOCIATION BETWEEN BREAST TUMOR SIZE AND LYMPH NODE INVOLVEMENT IN LOBULAR BREAST CANCERS IS PROGESTERONE RECEPTOR DEPENDENT. Annals of Oncology. 21. 31–32. 2 indexed citations

16.

Amant, Frédéric, Patrick Neven, & Kristel Van Calsteren. (2010). Treatment of cancer during pregnancy: the need for tailored strategies. Journal of Clinical Oncology. 28(18). 1 indexed citations

17.

Wildiers, Hans, Ben Van Calster, Lonneke V. van de Poll‐Franse, et al.. (2009). Relationship Between Age and Axillary Lymph Node Involvement in Women With Breast Cancer. Journal of Clinical Oncology. 27(18). 2931–2937. 58 indexed citations

18.

Brouwers, Barbara, Robert Paridaens, J.P. Lobelle, et al.. (2008). Clinicopathological Features of Inflammatory versus Noninflammatory Locally Advanced Nonmetastatic Breast Cancer. Tumor Biology. 29(4). 211–216. 10 indexed citations

19.

Depypere, Herman, F. De Prins, Petra De Sutter, et al.. (2002). Hormone receptor expression in Flemish patients with in situ and invasive primary breast cancer. Ghent University Academic Bibliography (Ghent University). 1 indexed citations

20.

Smith, Robert, Nisha Patel, G. E. D. Urquhart, et al.. (1990). Prevalence of HIV antibody and pregnancy in Tayside, 1984-9: background to screening.. BMJ. 301(6751). 518–520. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact